• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POSASR filed by Tricida Inc.

    6/13/23 6:51:41 AM ET
    $TCDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TCDA alert in real time by email
    POSASR 1 forms-3asr06132023.htm POSASR Document

    As filed with the Securities and Exchange Commission on June 13, 2023
    Registration No. 333-233189
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    POST-EFFECTIVE AMENDMENT NO. 1 TO
    FORM S-3ASR
    REGISTRATION STATEMENT NO. 333-233189
    UNDER
    THE SECURITIES ACT OF 1933
     
     
    TRICIDA, INC.
    (Exact Name of Registrant as Specified in Its Charter)
     
     

    DELAWARE46-3372526
    (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)
     
    2108 N Street
    Suite 4935
    Sacramento, CA 95816
    415-429-7800
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
     
     
    Geoffrey M. Parker
    Chief Operating Officer and Chief Financial Officer
    Tricida, Inc.
    2108 N Street
    Suite 4935
    Sacramento, CA 95816
    415-429-7800
    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
     




     
    Copies to:

    Geoffrey W. Levin, Esq.
    Istvan A. Hajdu, Esq.
    Sidley Austin LLP
    787 Seventh Avenue
    New York, NY 10019
    Telephone: (212) 839-5300
    Fax: (212) 839-5599
     
    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.
    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐
    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐
    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒
    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
     




     
     

    DEREGISTRATION OF SECURITIES
    This post-effective amendment (“Post-Effective Amendment”) relates to the registration statement on Form S-3ASR (the “Registration Statement”) filed by Tricida, Inc. (the “Registrant” or the “Company”) with the Securities and Exchange Commission (the “SEC”):
    1. Registration Statement on Form S-3ASR (File No. 333-233189), originally filed with the SEC on August 9, 2019, registering an undetermined number of shares of common stock, par value $0.001 per share, preferred stock, par value $0.001 per share, debt securities, warrants and units.    
    On January 11, 2023, the Company filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Court”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10024). On May 23, the Court entered an order confirming the Fifth Amended Chapter 11 Plan of Liquidation for Tricida, Inc. (the “Plan”). On June 12, 2023, the Plan became effective pursuant to its terms (the “Effective Date”).

    In connection with the Plan, on the Effective Date, the Registrant terminated all offerings of its securities pursuant to the Registration Statement. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration by means of a post-effective amendment any securities which remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration any and all securities of the Registrant registered pursuant to the Registration Statement that remain unsold or otherwise unissued as of the date hereof. The Registration Statement are hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statement.
     

    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Sacramento, State of California, on June 13, 2023.
     
    TRICIDA, INC. 
        
    By:/s/ Geoffrey M. Parker 
     Geoffrey M. Parker 
     
    Chief Operating Officer, Chief Financial Officer and
    Executive Vice President
     
    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the specified registration statement on Form S-3.



    Get the next $TCDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCDA

    DatePrice TargetRatingAnalyst
    4/13/2022$25.00Buy
    Goldman
    11/16/2021$7.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $TCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Orbimed Advisors Llc sold $2,205,635 worth of shares (10,280,947 units at $0.21)

      4 - Tricida, Inc. (0001595585) (Issuer)

      11/25/22 8:13:12 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Bonita David P sold $2,205,635 worth of shares (10,280,947 units at $0.21)

      4 - Tricida, Inc. (0001595585) (Issuer)

      11/25/22 8:08:35 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Alpern Robert J sold $27,695 worth of shares (131,879 units at $0.21), closing all direct ownership in the company

      4 - Tricida, Inc. (0001595585) (Issuer)

      11/25/22 4:13:54 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Toragen, Inc. Announces Appointment of Dr. Sandra Coufal, M.D. as CEO

      Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today that Dr. Sandra Coufal, M.D. will join Toragen as its new CEO. Dr. Coufal brings over 30 years of experience to Toragen as a physician and serial entrepreneur working with multiple successful companies in medicine, chemistry, biotechnology, material sciences, and digital technology. This press release features multimedia. View the full release here: https://www.businesswire.c

      2/9/22 4:38:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Financials

    Live finance-specific insights

    See more
    • Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

      Webcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). Primary Endpoint Analysis The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 pla

      10/24/22 7:00:00 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida Announces Second Quarter 2022 Financial Results

      Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and six months ended June 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in May 2022 that it stopped its VALOR-CKD renal outcomes trial early for administrative reasons as permitted by the existing study protocol to allow for six months of financial runway following the reporting of top-line results, which is anticipated to occur in October 2022. The VALOR-CKD trial has continued to accrue primary endpoint events as clinical trial subjects complete their participation in the study which, for the last subject, is currently projected to

      8/8/22 4:05:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 8, 2022

      SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022. Tricida will host a webcast and conference call at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows: Tricida Second Quarter Financial Results Conference CallMonday, August 8, 20224:30 pm Eastern Time  Webcast:IR.Tricida.com Dial-in:(800) 715-9871 International:(646) 307-1963 Conference ID:3576787 A replay of the webcast will be available on Tricida's website approximately two hours

      8/1/22 10:00:00 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Tricida Inc. (Amendment)

      SC 13G/A - Tricida, Inc. (0001595585) (Subject)

      2/14/23 4:16:07 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Tricida Inc. (Amendment)

      SC 13G/A - Tricida, Inc. (0001595585) (Subject)

      2/14/23 12:19:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Tricida Inc. (Amendment)

      SC 13G/A - Tricida, Inc. (0001595585) (Subject)

      2/14/23 8:58:08 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Tricida with a new price target

      Goldman initiated coverage of Tricida with a rating of Buy and set a new price target of $25.00

      4/13/22 7:21:51 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida upgraded by JP Morgan with a new price target

      JP Morgan upgraded Tricida from Underweight to Neutral and set a new price target of $7.00

      11/16/21 5:20:40 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tricida Announces Third Quarter 2022 Financial Results

      Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in October the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration

      11/14/22 4:05:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida Provides Strategic Update

      Tricida, Inc. (NASDAQ:TCDA), announced today that the Board of Directors has authorized Tricida to initiate a review of strategic alternatives to maximize stakeholder value. To facilitate this review, Tricida has engaged Stifel and its wholly owned affiliate, Miller Buckfire, to serve as investment banking advisors and SierraConstellation Partners LLC to serve as a financial advisor. This strategic review may include consideration of the sale of the Company and/or its assets. Tricida is also currently evaluating plans to reduce operating expenses and anticipates initiating and announcing these plans in November 2022. The Board of Directors and Tricida intend to conduct a thorough review of

      11/2/22 4:05:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

      Webcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). Primary Endpoint Analysis The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 pla

      10/24/22 7:00:00 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Tricida Inc.

      EFFECT - Tricida, Inc. (0001595585) (Filer)

      6/20/23 12:15:13 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Tricida Inc.

      15-12G - Tricida, Inc. (0001595585) (Filer)

      6/13/23 6:55:49 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Tricida Inc.

      S-8 POS - Tricida, Inc. (0001595585) (Filer)

      6/13/23 6:53:19 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care